{"entity":{"id":"nct07043907","kind":"trial","name":"PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC","aka":[],"tldr":"A phase 2 trial in lung cancer, run by Shenzhen Celconta Life Science Co., Ltd., not yet recruiting.","summary":"PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC is a phase 2, interventional study registered as NCT07043907 by Shenzhen Celconta Life Science Co., Ltd., with a registry enrolment figure of 115 participants, started 2025-07-08 and due to reach its primary completion in 2028-07-08. Interventions recorded: PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy. Conditions listed: Stage IIIA Non-small Cell Lung Cancer. Primary outcome: Incidence and severity of adverse events (AEs); Disease Free Surviva Percentage（DFS%）. Lung eligibility wording from the registry: \"Patients with histologically confirmed stage IIIA NSCLC (T4N0M0, T3-4N1M0, T1a-2bN2M0) who underwent R0 resection and received postoperative adjuvant chemotherapy (Exclusion of EGFR sensitizing mutations and ALK fusion); and who received the first dose of PANK-003 cell injection combined with postop\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07043907","url":"https://clinicaltrials.gov/study/NCT07043907"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07043907","phase":"2","setting":"A Single-center, Single-arm Exploratory Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA Non-Small Cell Lung Cancer","sponsor":"Shenzhen Celconta Life Science Co., Ltd.","enrolled":115,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07043907/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}